Abstract: The aim of this study is to determine the cumulative incidence of, and the risk factors for, the development of nontuberculous mycobacteria pulmonary disease (NTM-PD) following lung cancer surgery. We retrospectively analyzed patients with non-small cell lung cancer who underwent surgical resection between 2010 and 2016. Patients who met all the diagnostic criteria in the NTM guidelines were defined as having NTM-PD. Additionally, we classified participants as NTM-positive when NTM were cultured in respiratory specimens, regardless of the diagnostic criteria. We followed 6503 patients for a median of 4.89 years, and NTM-PD and NTM-positive diagnoses occurred in 59 and 156 patients, respectively. The cumulative incidence rates of NTM-PD and NTM-positive were 2.8% and 5.9% at 10 years, respectively. Mycobacterium avium complex was the most commonly identified pathogen, and half of the NTM-PD patients had cavitary lesions. Several host-related factors (age > 65 years, body mass index $\leq 18.5$ kg/m$^2$, interstitial lung disease, bronchiectasis, and bronchiolitis) and treatment-related factors (postoperative pulmonary complications and neoadjuvant/adjuvant treatments) were identified as risk factors for developing NTM-PD and/or being NTM-positive after lung cancer surgery. The incidences of NTM-PD and NTM-positive diagnoses after lung cancer surgery were not low, and half of the NTM-PD patients had cavitary lesions, which are known to progress rapidly and often require treatment. Therefore, it is necessary to raise awareness of NTM-PD development after lung cancer surgery.

Keywords: nontuberculous mycobacterium; lung cancer; surgery

1. Introduction

Lung cancer remains a major problem because the number of patients is increasing worldwide, and it remains the most common cause of cancer death [1]. However, as low-dose chest computed tomography (CT) is increasingly being used for cancer screening in the general population at risk for lung cancer, the number of patients diagnosed in earlier stages who can undergo surgical treatment has increased [2]. Additionally, clinical staging [3], surgical techniques [4], and neoadjuvant and adjuvant therapies [5,6] have advanced over the last few decades. Although lung cancer treatment is still a challenge, its long-term survival rates should gradually improve with these advances, especially in early-stage lung cancers [7].
Surgical resection is the gold standard treatment for early-stage lung cancer [8]. Unfortunately, patients who develop a postoperative pulmonary complication (PPC) after the surgical resection of lung cancer experience worse long-term outcomes [9]. However, there are insufficient data on the incidence and impact of chronic complications, particularly those associated with chronic pulmonary infections. Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms that cause chronic pulmonary disease (PD), and the burdens of NTM-PD are increasing globally [10,11]. Furthermore, the incidence and prevalence of NTM-PD rapidly increased in South Korea from 2003 to 2016 [12]. Well-known risk factors for NTM-PD include an older age, underlying structural PD such as chronic obstructive lung disease (COPD), bronchiectasis, interstitial lung disease (ILD), a previous history of pulmonary tuberculosis (TB) [13,14], and the use of immunosuppressant medications [15,16].

Studies on the relationship between chronic pulmonary infection, not NTM-PD, and lung cancer surgery have been reported. Previous studies reported that lung cancer surgery is one of the risk factors for developing chronic pulmonary aspergillosis [17,18]. To the best of our knowledge, few studies have investigated the development of NTM-PD after the long-term follow-up in patients who underwent lung cancer resection surgery. Therefore, we aimed to determine the cumulative incidence of NTM-PD after lung cancer surgery and evaluate the risk factors related to the development of NTM-PD.

2. Materials and Methods

2.1. Study Population and Data Collection

This was a retrospective cohort study. We screened the medical data of patients with non-small cell lung cancers (NSCLC) who underwent lung resection surgery between January 2010 and December 2016 from the Lung Cancer Surgery Registry at Samsung Medical Center, a 1997 bed referral hospital in South Korea. Patients with a concurrent diagnosis or a previous history of NTM-PD at the time of surgery were excluded. Even when the diagnostic criteria for NTM-PD were not fully satisfied, patients with culture-positive NTM from the respiratory specimen obtained before surgery were also excluded. Additionally, patients who showed granulomatous inflammation in surgical specimens of lung cancer in which NTM infection could not be ruled out were excluded from this study.

We used the same database to gather the following information: patient-related factors, such as age, sex, body mass index (BMI), a history of smoking, underlying pulmonary diseases, other comorbidities, and CT findings at the time of the lung cancer diagnosis (TB sequelae, bronchiectasis, and centrilobular bronchiolitis); cancer-related factors, such as histologic type, location of the tumor, and the clinical/pathological stage of cancer; treatment-related factors, including the neoadjuvant or adjuvant treatments used, the surgical approach, the extent of surgical resection, and the development of any PPCs within 30 days after surgery. Underlying pulmonary diseases included a previous history of pulmonary TB, small airway disease (COPD, asthma), and ILD. The tumor was staged using the Seventh Edition of the American Joint Committee on Cancer [19]. A PPC was defined as the development of any intrathoracic complications during the patient’s hospital stay or during a readmission within 30 days after surgery [20]. Patient follow-up data were last updated in February 2021.

This study obtained approval from the Institutional Review Board (IRB no. 2021-04-016) to review and publish information from patient records, and the requirement for informed consent was waived because the patient information was de-identified and anonymized prior to the retrospective analysis.

2.2. Diagnosis of NTM

After surgical resection for NSCLC, most patients were followed-up for at least five years by a thoracic surgeon. Patients with pre-existing or newly developed pulmonary disease were jointly followed-up by a pulmonologist [17]. Physical examinations, laboratory tests, chest radiographies, and chest CT scans were regularly performed at scheduled intervals during follow-up visits. When the development of NTM-PD was suspected based
on chest CT images and pulmonary symptoms, patients were referred to a pulmonologist, and further diagnostic tests were performed as needed. The diagnosis of NTM-PD was established as follows: (i) cultured in at least two separate sputum samples or (ii) cultured in at least one or more bronchoalveolar lavage/washing specimens or (iii) lung biopsy with mycobacterial histopathologic features and positive for NTM in tissue culture or in one or more sputum or bronchial lavage fluid cultures [21]. Of course, the final diagnosis was accompanied by an appropriate exclusion of other diseases.

The diagnosis of NTM-PD usually takes months to years even in patients with suspicious clinicoradiological findings [22]. In consideration of this cohort’s many deaths due to lung cancer or loss to follow-up, the following additional situations were also defined: (1) suspicious NTM-PD was defined when the microbiologic criteria were not satisfied, such as only one sputum culture-positive specimen or insufficient identification test results for NTM species; (2) NTM-positive was defined as the sum of all patients with NTM-PD and suspicious NTM-PD.

Acid-fast bacilli (AFB) smears and cultures were prepared using standard methods [23]. All specimens were cultured both on 3% Ogawa solid media (Shinyang, Seoul, South Korea) and in liquid broth media in mycobacterial growth indicator tubes (Becton, Dickinson and Co., Sparks, MD, USA). NTM species were identified using nested multiplex polymerase chain reaction and a reverse-hybridization assay of the internal transcribed spacer region (AdvanSureTM Mycobacteria GenoBlot Assay; LG Life Sciences, Seoul, Korea) [24].

The radiological classification of patients with NTM-positive results was as follows. The fibrocavitary form of NTM-PD was defined by the presence of cavitary opacities predominantly in the upper lobes. The nodular bronchiectatic (NB) type was characterized by the presence of multifocal bronchiectasis and clusters of small nodules [25]. Additionally, the NB form was divided into a “with cavity” and a “without cavity” form.

2.3. Statistical Analyses
The data are presented as a number (%) for categorical variables and as the median (interquartile range [IQR]) for continuous variables. Data were compared using the Chi-square test or Fisher’s exact test for categorical variables, and the Mann–Whitney U test for continuous variables. P values for categorical variables with an ordinal scale were calculated with the use of a Mantel–Haenszel test (trend test). The Kaplan–Meier method was used to estimate the cumulative incidence of NTM-PD and overall survival (OS) after the lung cancer surgery.

A multivariable Cox proportional hazard analysis with a backward stepwise selection with \( p < 0.05 \) for entry and \( p > 0.10 \) for removal was used to identify the independent risk factors related to NTM-PD development. The clinical stage of the tumor was not included in the multivariable analysis because it had significant collinearity with neoadjuvant and adjuvant treatments. All analyses were performed for both patients with NTM-PD and those who were NTM-positive, respectively. All tests were two-sided, and a \( p \)-value < 0.05 was considered significant. All statistical analyses were performed using SPSS software (IBM SPSS Statistics ver. 27, Chicago, IL, USA).

3. Results
3.1. Study Population
Between January 2010 and December 2016, 6789 patients underwent lung cancer surgery, and 6503 patients were finally analyzed (Figure 1). Of the 6503 patients, 156 (2.4%) patients had one or more positive results of NTM culture in their respiratory specimens after lung cancer surgery, and 59 (0.9%) patients were confirmed to have progressed to NTM-PD.

The patients were followed up for a median of 4.89 (IQR: 3.31–6.32) years, and the 5-year survival rate was 76.7% (Figure 2A). During the follow-up period after lung cancer surgery, 59 patients developed NTM-PD at a median of 3.41 (IQR: 2.17–5.08) years (Figure 2B). The cumulative incidences were 0.1%, 0.5%, 0.9%, and 2.8% at 1, 3, 5, and 10 years, respectively, and the incidence rate was 1.9 (95% confidence interval [CI]: 1.5–2.5) per 1000 person-years. Including suspicious NTM-PD, 156 patients had NTM-positive
results on their respiratory specimens at a median of 2.79 (IQR: 1.43–4.55) years. The cumulative incidences for NTM-positive results were 0.5%, 1.5%, 2.5%, and 5.9% at 1, 3, 5, and 10 years, respectively, and the incidence rate was 5.1 (95% CI: 4.3–6.0) per 1000 person-years.

**Figure 1.** Flow diagram of the study population. * NTM culture (+) from respiratory specimens without an identification test for NTM species (n = 44), NTM culture (+) from only one sputum sample with an identification test for NTM species (n = 7), NTM culture (+) from only one sputum sample without an identification test for NTM species (n = 182). † Of these 41 patients, 27 patients were included in “Patients with NTM-PD at the time of lung cancer diagnosis (n = 16)” or “Patients with suspicious NTM infection at the time of lung cancer diagnosis (n = 11)”.* ‡ NTM culture (+) from respiratory specimens without an identification test for NTM species (n = 68), NTM culture (+) from only one sputum sample with an identification test for NTM species (n = 25), NTM culture (+) from at least two sputum samples with only one identification test for NTM species (n = 4). NTM, nontuberculous mycobacteria.

**Figure 2.** (A) The overall survival rate of the study population and (B) the cumulative incidence of NTM-PD and NTM-positive results after lung resection surgery. NTM-PD, nontuberculous mycobacterial pulmonary disease.
3.2. Baseline Characteristics of Patients Who Developed NTM-PD and Were NTM-Positive after Lung Cancer Surgery

The median age of the study population was 63 years, and 61.2% were male (Table 1). Patients with NTM-PD had a greater distribution of being > 65 years (59.3% vs. 42.7%, \( p = 0.010 \)), having a smoking history (\( p = 0.007 \)), and having a BMI \( \leq 18.5 \text{ kg/m}^2 \) (10.2% vs. 2.6%, \( p = 0.005 \)). In addition, the proportion of patients with bronchiectasis (18.6% vs. 6.1%, \( p = 0.001 \)) and centrilobular bronchiolitis (13.6% vs. 2.3%, \( p < 0.001 \)) on CT images at the time of the lung cancer diagnosis was higher.

Table 1. The baseline characteristics of patients with NSCLC and the development of NTM-PD after lung resection.

| Variables                        | NTM-PD (–) \((n = 6444)\) | NTM-PD (+) \((n = 59)\) | \( p \) |
|----------------------------------|----------------------------|-------------------------|-------|
| Age, years                       | 63 (56–69)                 | 67 (59–69)              | 0.053 |
| Age > 65 years                   | 2752 (42.7)                | 35 (59.3)               | 0.010 |
| Sex, male                        | 3938 (61.1)                | 41 (69.5)               | 0.189 |
| Smoking status \((n = 6501)\)    |                            |                         |       |
| Never smoker                     | 2727 (42.3)                | 22 (37.3)               |       |
| Ex-smoker                        | 2029 (31.5)                | 11 (18.6)               |       |
| Current smoker                   | 1686 (26.2)                | 26 (44.1)               |       |
| Pack-years \((n = 3761)\)       | 30 (20–45)                 | 35 (16–50)              | 0.694 |
| BMI, kg/m^2                      | 23.9 (22.0–25.8)           | 21.9 (20.2–23.8)        | <0.001|
| BMI \( \leq 18.5 \text{ kg/m}^2 \) | 167 (2.6)                 | 6 (10.2)                | 0.005 |
| Comorbidity                      |                            |                         |       |
| Pulmonary disease                |                            |                         |       |
| History of pulmonary TB          | 690 (10.7)                 | 11 (18.6)               | 0.058 |
| COPD/Asthma                      | 1741 (27.0)                | 18 (30.5)               | 0.458 |
| Interstitial lung disease        | 72 (1.1)                   | 2 (3.4)                 | 0.145 |
| DM                               | 1015 (15.8)                | 6 (10.2)                | 0.241 |
| Hypertension                     | 2338 (36.3)                | 25 (42.4)               | 0.333 |
| Chronic heart disease            | 447 (6.9)                  | 4 (6.8)                 | >0.999|
| Chronic renal disease            | 89 (1.4)                   | 0 (0.0)                 | >0.999|
| Cerebrovascular disease          | 375 (5.8)                  | 0 (0.0)                 | 0.049 |
| Previous malignancy              | 890 (13.8)                 | 9 (15.3)                | 0.749 |
| Clinical stage at diagnosis      |                            |                         | 0.115 *|
| Stage I                          | 4450 (69.1)                | 37 (62.7)               |       |
| Stage II                         | 1121 (17.4)                | 8 (13.6)                |       |
| Stage III                        | 812 (12.6)                 | 14 (23.7)               |       |
| Stage IV                         | 61 (0.9)                   | 0 (0.0)                 |       |
| Tumor histology                  |                            |                         | 0.516 |
| Adenocarcinoma                   | 4559 (70.7)                | 43 (72.9)               |       |
| Squamous cell carcinoma          | 1498 (23.2)                | 11 (18.6)               |       |
| Others †                         | 387 (6.0)                  | 5 (8.5)                 |       |
| Location of lung cancer          |                            |                         | 0.123 |
| Right                            | 3728 (57.9)                | 40 (67.8)               |       |
| Left                             | 2716 (42.1)                | 19 (32.2)               |       |
| CT findings                      |                            |                         |       |
| TB sequelae                      | 274 (4.3)                  | 3 (5.1)                 | 0.740 |
| Bronchiectasis                   | 391 (6.1)                  | 11 (18.6)               | 0.001 |
| Centrilobular bronchiolitis      | 148 (2.3)                  | 8 (13.6)                | <0.001|

Data are presented as n (%) or the median (interquartile range). NSCLC, non-small cell lung cancer; NTM-PD, non-tuberculous mycobacterial pulmonary disease; BMI, body mass index; TB, tuberculosis; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus. * \( p \) values were calculated with the use of a Mantel–Haenszel test (trend test). † Includes large cell neuroendocrine carcinoma, adenosquamous carcinoma, pleomorphic carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, epithelial myoepithelial carcinoma, and carcinoid tumor.

Similar trends were observed when the same analysis was performed after dividing patients by their NTM culture results for this cohort (Table S1). In addition to the trends of the characteristics mentioned above, patients who developed NTM-positive results were
more likely to be male (73.7% vs. 60.9%, \( p = 0.001 \)), have a previous history of pulmonary TB (22.4% vs. 10.5%, \( p < 0.001 \)), COPD, or asthma (39.7% vs. 26.7%, \( p < 0.001 \)), and have a higher clinical stage at diagnosis (\( p \) for trend = 0.001) than those who did not develop the NTM-positive results. Among the factors associated with lung cancer treatment, patients who developed NTM-PD more commonly received neoadjuvant treatment (20.3% vs. 9.5%, \( p = 0.005 \)) than those who did not (Table 2). In addition, the incidence of PPCs (27.1% vs. 16.8%, \( p = 0.035 \)) was higher in patients with NTM-PD than it was in those without NTM-PD.

**Table 2.** The treatment profile for NSCLC and the development of NTM-PD after lung resection.

| Variables                          | NTM-PD (–) (\( n = 6444 \)) | NTM-PD (+) (\( n = 59 \)) | \( p \) |
|-----------------------------------|-------------------------------|---------------------------|-------|
| Neoadjuvant treatment             |                               |                           |       |
| No                                | 5832 (90.5)                   | 47 (79.7)                 | 0.005 |
| Yes                               | 612 (9.5)                     | 12 (20.3)                 |       |
| CCRT                              | 531 (8.2)                     | 10 (16.9)                 | 0.028 |
| Chemotherapy                      | 75 (1.2)                      | 1 (1.7)                   | 0.502 |
| Radiotherapy                      | 6 (0.1)                       | 1 (1.7)                   | 0.082 |
| Surgical approach                 |                               |                           | 0.067 |
| VATS                              | 4024 (62.4)                   | 30 (50.8)                 |       |
| Thoracotomy                       | 2420 (37.6)                   | 29 (49.2)                 |       |
| Extent of surgical resection      |                               |                           | 0.238 * |
| Sublobar resection                | 1082 (16.8)                   | 6 (10.2)                  | >0.999 |
| Wedge resection                   | 630 (9.8)                     | 4 (6.8)                   | >0.999 |
| Segmentectomy                     | 452 (7.0)                     | 2 (3.4)                   |       |
| Lobectomy                         | 4891 (75.9)                   | 50 (84.7)                 |       |
| Bilobectomy                       | 248 (3.8)                     | 1 (1.7)                   |       |
| Pneumonectomy                     | 223 (3.5)                     | 2 (3.4)                   |       |
| Pathologic stage \(^†\)           |                               |                           | >0.999 * |
| I                                 | 4109 (64.4)                   | 36 (63.2)                 |       |
| II                                | 1193 (18.7)                   | 12 (21.1)                 |       |
| III                               | 1007 (15.8)                   | 8 (14.0)                  |       |
| IV                                | 74 (1.2)                      | 1 (1.8)                   |       |
| PPC \(^‡\)                        | 1082 (16.8)                   | 16 (27.1)                 | 0.035 |
| Adjuvant treatment \(^§\)         |                               |                           | 0.609 |
| No                                | 4636 (72.5)                   | 41 (69.5)                 |       |
| Yes                               | 1760 (27.5)                   | 18 (30.5)                 |       |
| CCRT                              | 327 (5.1)                     | 2 (3.4)                   | 0.769 |
| Chemotherapy                      | 1129 (17.5)                   | 11 (18.6)                 | 0.821 |
| Radiotherapy                      | 304 (4.7)                     | 5 (8.5)                   | 0.203 |

Data are presented as \( n (\%) \). NSCLC, non-small cell lung cancer; NTM-PD, nontuberculous mycobacteria pulmonary disease; CCRT, concurrent chemoradiotherapy; VATS, video-assisted thoracoscopic surgery; PPC, postoperative pulmonary complication. \(^*\) \( p \) values were calculated with the use of a Mantel–Haenszel test (trend test). \(^†\) Except for 63 patients where no residual tumor appeared in the surgical specimen after neoadjuvant treatment (pathologic complete response [ypCR]). \(^‡\) Pneumothorax and/or prolonged air leak (\( n = 502 \)), respiratory failure that required mechanical ventilation (\( n = 253 \)), pneumonia (\( n = 231 \)), pleural effusion (\( n = 150 \)), others (atelectasis, bronchopleural fistula, pulmonary thromboembolism, etc.) (\( n = 291 \)). Some patients had more than one complication. \(^§\) Excluded 48 patients due to data unavailability.

Along with these differences, patients with NTM-positive results were also more likely to receive an adjuvant treatment (35.9% vs. 27.9%, \( p = 0.018 \)) than those without NTM-positive results (Table S2). There were no statistical differences in the extent of surgical resection and pathologic stage whether patients developed NTM-PD or not as well as among patients with or without NTM-positive results.

Among the 59 NTM-PD patients, Mycobacterium avium complex (MAC) was the most common pathogen (Table 3). NTM-PD patients with the NB form accounted for 70%, and the NB form with cavity lesions accounted for 20%. In the 97 patients classified with suspicious NTM-PD, the reasons for not satisfying the microbiologic criteria were as follows: NTM culture (+) from respiratory specimens without an identification test for NTM species (\( n = 68 \)), NTM culture (+) from only one sputum sample with an identification test for NTM species (\( n = 25 \)), and NTM culture (+) from at least two sputum samples with
only one identification test for NTM species \((n = 4)\). In suspicious NTM-PD patients, about 80\% of patients had the NB form, and four (4.1\%) of them had cavity lesions (Table S3).

**Table 3. Characteristics of definitive NTM-PD.**

| Variables                  | \(n\) (%) |
|---------------------------|-----------|
| **NTM-PD \((n = 59)\)**   |           |
| **Etiology**              |           |
| \(M. avium\)              | 15 (25.4) |
| \(M. intracellulare\)     | 35 (59.3) |
| \(M. massiliense\)        | 2 (3.4)   |
| \(M. abscessus\)          | 1 (1.7)   |
| Others *                  | 6 (10.2)  |
| **Radiologic findings**   |           |
| Nodular bronchiectatic form | 41 (69.5) |
| Without cavity            | 29 (49.2) |
| With cavity               | 12 (20.3) |
| Fibrocavitary form         | 18 (30.5) |

Data are presented as \(n\) (%). NTM-PD, nontuberculous mycobacteria pulmonary disease. *M. fortuitum complex \((n = 2)\), M. kansasii \((n = 1)\), M. szulgai \((n = 1)\), M. peregrinum \((n = 1)\), and M. gordonae \((n = 1)\).

### 3.3. Factors Associated with the Development of NTM-PD and NTM-Positive Results

The emergence of NTM-PD was independently associated with an age > 65 years \((\text{adjusted hazard ratio (aHR)}: 2.44; 95\% \text{ CI}: 1.43–4.16; p = 0.001)\), a BMI \(\leq 18.5 \text{ kg/m}^2\) \((\text{aHR}: 3.85; 95\% \text{ CI}: 1.62–9.16; p = 0.002)\), ILD \((\text{aHR}: 8.23; 95\% \text{ CI}: 1.96–34.51; p = 0.004)\), bronchiectasis \((\text{aHR}: 2.38; 95\% \text{ CI}: 1.16–4.91; p = 0.019)\) or centrilobular bronchiolitis \((\text{aHR}: 3.91; 95\% \text{ CI}: 1.71–8.93; p = 0.001)\) on CT imaging at the time of lung cancer diagnosis, PPCs \((\text{aHR}: 1.90; 95\% \text{ CI}: 1.07–3.39; p = 0.029)\), and treatment with both chemotherapy and radiotherapy \((\text{aHR}: 2.70; 95\% \text{ CI}: 1.42–5.12; p = 0.002)\) (Table 4).

In contrast, the development of NTM-positive (NTM-PD and suspicious NTM-PD) results was not associated with a lower BMI out of the seven variables, while ever-smokers \((\text{aHR}: 1.48; 95\% \text{ CI}: 1.02–2.13)\), a history of pulmonary TB \((\text{aHR}: 2.27; 95\% \text{ CI}: 1.55–3.31; p < 0.001)\), and thoracostomy \((\text{aHR}: 1.53; 95\% \text{ CI}: 1.07–2.21; p = 0.021)\) were additionally related (Table S4).

**Table 4. Prognostic factors associated with the development of NTM-PD after lung resection for NSCLC \((n = 6503)\).**

| Variables                   | **Univariable Cox** | **Multivariable Cox** |
|-----------------------------|---------------------|-----------------------|
| **Host-related factors**    | **Unadjusted HR**   | **Adjusted HR**       |
| * p                         | 95% CI              | 95% CI                |
| Age > 65 years              | 2.72 (1.61–4.58)    | <0.001                | 2.44 (1.43–4.16) | 0.001 |
| Sex, male                   | 1.75 (1.01–3.05)    | 0.047                 |                      |
| BMI \(\leq 18.5 \text{ kg/m}^2\) | 5.60 (2.41–13.04)  | <0.001                | 3.85 (1.62–9.16)    | 0.002 |
| Smoking history, yes        | 1.50 (0.88–2.54)    | 0.134                 |                      |
| History of pulmonary TB     | 1.98 (1.03–3.82)    | 0.041                 |                      |
| COPD/Asthma                 | 1.35 (0.77–2.35)    | 0.292                 |                      |
| ILD                         | 7.34 (1.79–30.16)   | 0.006                 | 8.23 (1.96–34.51)    | 0.004 |
| Diabetes mellitus           | 0.70 (0.30–1.64)    | 0.413                 |                      |
| History of malignancy       | 1.14 (0.56–2.32)    | 0.717                 |                      |
| CT findings                 |                      |                       |                      |
| TB sequelae                 | 1.24 (0.39–3.95)    | 0.721                 |                      |
| Bronchiectasis              | 3.33 (1.73–6.42)    | <0.001                | 2.38 (1.16–4.91)     | 0.019 |
| Centrilobular bronchiolitis | 6.72 (3.19–14.16)   | <0.001                | 3.91 (1.71–8.93)     | 0.001 |
### Table 4. Cont.

| Variables                  | Univariable Cox | Multivariable Cox |
|----------------------------|-----------------|-------------------|
|                            | Unadjusted HR   | Adjusted HR       |
|                            | (95% CI)        | (95% CI)          |
|                            | *p*             | *p*               |
| **Cancer-related factors** |                 |                   |
| Tumor histology            |                 |                   |
| Adenocarcinoma             | Reference       |                   |
| Squamous cell carcinoma    | 1.04 (0.53–2.01)| 0.915             |
| Others *                   | 1.79 (0.71–4.51)| 0.219             |
| **Treatment-related factors** |                 |                   |
| Surgical approach          |                 |                   |
| VATS                       | Reference       |                   |
| Thoracotomy                | 2.14 (1.28–3.56)| 0.004             |
| Extent of surgical resection |               |                   |
| Lobectomy                  | Reference       |                   |
| Sublobar resection         | 0.53 (0.23–1.24)| 0.144             |
| Bilobectomy                | 0.48 (0.07–3.45)| 0.463             |
| Pneumonectomy              | 1.32 (0.32–5.43)| 0.700             |
| PPC †                      | 2.23 (1.26–3.96)| 0.006             |
| Neoadjuvant and adjuvant treatment | |                   |
| No                         | Reference       |                   |
| CTx or RTx alone           | 1.00 (0.48–2.07)| 0.993             |
| CTx and RTx both           | 2.24 (1.19–4.22)| 0.012             |
|                            | 2.70 (1.42–5.12)| 0.002             |

NTM-PD, nontuberculous mycobacteria pulmonary disease; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidential interval; BMI, body mass index; TB, tuberculosis; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CT, computed tomography; VATS, video-assisted thoracoscopic surgery; PPC, postoperative pulmonary complication; CTx, chemotherapy; RTx, radiotherapy. * Includes large cell neuroendocrine carcinoma, adenosquamous carcinoma, pleomorphic carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, epithelial myoepithelial carcinoma, and carcinoid tumor. † Pneumothorax and/or prolonged air leak (n = 502), respiratory failure that required mechanical ventilation (n = 253), pneumonia (n = 231), pleural effusion (n = 150), others (atelectasis, bronchopleural fistula, pulmonary thromboembolism, etc.) (n = 291). Some patients had more than one complication.

### 4. Discussion

During the long-term follow-up of 6503 patients undergoing lung cancer surgery, NTM-PD and NTM-positive patients occurred as 2.8% and 5.9% of the 10-year cumulative incidence, respectively. Among the total 59 patients who developed NTM-PD, MAC was the most common pathogen, and the incidence rate of the cavitary disease was 50%. Risk factors related to the development of NTM-PD were an older age, a lower BMI, underlying ILD, bronchiectasis and centrilobular bronchiolitis upon CT imaging, PPCs, and treatment with chemotherapy and radiotherapy. In addition, ever-smokers, a history of pulmonary TB, and thoracotomies were found to be factors that influenced whether a patient was NTM culture-positive.

Although the incidence of NTM-PD varies by region, it has been increasing worldwide, over the past few decades. In a tertiary referral hospital setting in South Korea, one study reported incidence rates of NTM-PD and NTM-positive to be 4.8 and 19.6 per 100,000 person-years in 2016, respectively [26]. In our study, the incidence rates of NTM-PD and NTM-positive results after lung cancer surgery were 1.9 and 5.1 per 1000 person-years, respectively. These incidence rates were approximately 40-fold and 26-fold higher, respectively, than for the general patient population that visits tertiary hospitals in South Korea.

The association between lung cancer surgery and the development of NTM-PD is not well established. There is only one previous study that reported 23 patients with NTM growth in at least one respiratory specimen culture of about 400 patients undergoing lung cancer surgery, and 12 patients met the NTM-PD diagnostic criteria [27]. They analyzed a small number of patients and focused on survival rather than incidence rate, whereas our study provided unprecedented evidence of the NTM-PD incidence after lung cancer surgery.
surgery by presenting long-term follow-up results using the large-scale cohort data of approximately 7000 patients.

Similar to previous findings that the majority of NTM-PD is caused by MAC [28,29], MAC was the most common NTM species in our study. According to a large study from South Korea, the non-cavitary NB form accounts for about 70% of cases [29]. Compared to this study, we reported that half of the NTM-PD patients had cavity lesions. Considering that cavity lesions in NTM-PD were strongly associated with a poor outcome [29], we suggest that NTM-PD should be intensively monitored in patients after lung cancer surgery.

In our study, an age > 65 years and a BMI $\leq$ 18.5 kg/m$^2$ predisposed patients to the development of NTM-PD. These results are similar to those reported by previous studies in the general population [10,30]. Comorbidities with structural lung disease, such as a previous history of pulmonary TB, bronchiectasis, COPD, and ILD, were also well-known risk factors for developing NTM-PD [15,31,32]. In our study, a previous history of pulmonary TB, ILD, and bronchiectasis were also related to the development of NTM-PD, except COPD. The use of inhaled corticosteroids in COPD patients was a strong risk factor for developing NTM-PD [33]. In our study, most patients diagnosed with COPD were found through preoperative lung function tests, and their lung function was guaranteed to be adequate for surgery. These patients were distinct from those with advanced COPD, who had structural defects and used inhaled corticosteroids. Consequently, COPD should not have emerged as a risk factor in our analysis.

The presence of bronchiectasis or centrilobular bronchiolitis on CT imaging at the time of a lung cancer diagnosis was a related factor for developing NTM-PD in this study. However, some patients with bronchiectasis or centrilobular bronchiolitis on CT images might already have had NTM-PD at that time. A diagnosis of NTM-PD requires repeat tests using respiratory specimens, and the results of these tests need to meet the diagnostic criteria; therefore, NTM-PD detection might be underestimated at the time of a lung cancer diagnosis. Due to our concerns about this very situation, we excluded not only patients who had already been diagnosed with NTM-PD, but also those confirmed to be culture-positive for NTM even once based on respiratory specimens and those with suspicious pathologic results on surgical specimens.

We demonstrated that a PPC was a factor that influenced the development of NTM-PD. This finding suggested that structural defects caused by PPCs might contribute to the development of NTM-PD. Additionally, patients who underwent an open thoracotomy were at a greater risk of developing NTM-PD compared with those who received video-assisted thorascoscopic surgery. We suggest that patients who undergo a thoracotomy are likely to have structural defects present, such as pleural adhesion, which may contribute to the development of NTM-PD after lung resection surgery. Meanwhile, treatment with chemotherapy and radiotherapy increased the risk of NTM-PD, which means that the immunocompromised state that results from chemotherapy and the lung injuries caused by radiotherapy contributed to the development of the NTM-PD [34,35]. To our knowledge, the present study is the first to demonstrate that lung cancer surgery-related factors and PPCs were related to the development of NTM-PD.

This study had several limitations. First, this was a retrospective cohort study of a single institution, which can be a source of selection bias. Second, it is possible that the results were underestimated because a diagnosis of NTM-PD requires repeated AFB cultures and NTM species identifications and usually takes several months to diagnose [22]. Because of this possibility, we included cases suspicious for NTM-PD in the analysis that did not satisfy the microbiological criteria but still reported NTM growth. Previous studies also found that a single NTM growth isolate was associated with the future occurrence of NTM-PD [36]. Despite these limitations, we found that previous risk factors of NTM-PD could be risk factors even in patients who are followed-up for a long time after lung cancer surgery. We also suggest that surgical-related factors and neoadjuvant/adjuvant therapy might influence the development of NTM-PD.
5. Conclusions

The cumulative incidence rate of NTM-PD at 10 years after lung cancer surgery was 2.8% (1.9 cases per 1000 person-years), which was approximately 40 times higher than that of the general population in South Korea. Half of NTM-PD patients had a cavitary lesion, which progresses rapidly and often requires treatment. In addition, host-related factors commonly known as risk factors for NTM-PD development were also identified as risk factors in patients with lung cancer surgery. Notably, lung cancer treatment-related factors, such as thoracotomies, PPCs, and additional treatment with chemotherapy and radiotherapy, were associated with the development of NTM-PD or NTM-positive results. Therefore, it is necessary to raise awareness of NTM-PD development after lung cancer surgery, especially in patients with risk factors.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12051086/s1, Table S1: The baseline characteristics of patients with NSCLC and the development of NTM-positive results after lung resection; Table S2: The treatment profile for NSCLC and the development of NTM-positive results after lung resection; Table S3: Characteristics of suspicious NTM-PD; Table S4: Prognostic factors associated with the development of NTM-positive results after lung resection for NSCLC.

Author Contributions: Conceptualization and methodology, B.-H.J., B.-G.K. and Y.S.C.; validation, Y.S.C., B.-H.J. and H.K.; formal analysis, B.-G.K. and Y.S.C.; investigation and resources, Y.S.C., J.H.C., H.K.K., J.K., Y.M.S., S.H.S., K.L., S.-W.U., H.K., J.H.C., H.K.K., J.K. and Y.M.S.; project administration, B.-H.J.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Samsung Medical Center (IRB no. 2021-04-016) (Approval date: 6 April 2021).

Informed Consent Statement: Patient consent was waived because the patient information was de-identified and anonymized prior to the retrospective analysis.

Data Availability Statement: Data and material are available on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bade, B.C.; Dela Cruz, C.S. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest. Med. 2020, 41, 1–24. [CrossRef] [PubMed]
2. Henschke, C.I.; Yankelevitz, D.F.; Libby, D.M.; Pasmanter, M.W.; Smith, J.P.; Miettinen, O.S. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006, 355, 1763–1771.
3. Um, S.W.; Kim, H.K.; Jung, S.H.; Han, J.; Lee, K.J.; Park, H.Y.; Choi, Y.S.; Shim, Y.M.; Ahn, M.J.; Park, K.; et al. Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. J. Thorac. Oncol. 2015, 10, 331–337. [CrossRef] [PubMed]
4. Whitson, B.A.; Groth, S.S.; Duval, S.J.; Swanson, S.J.; Maddaus, M.A. Surgery for early-stage non-small cell lung cancer: A systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann. Thorac. Surg. 2008, 86, 2008–2016, discussion 2016–2008. [CrossRef]
5. Scagliotti, G.V.; Novello, S. Current development of adjuvant treatment of non-small-cell lung cancer. Clin. Lung Cancer 2004, 6 (Suppl. 2), S63–S70. [CrossRef] [PubMed]
6. Blumenthal, G.M.; Bunn, P.A., Jr.; Chaft, J.E.; McCoach, C.E.; Perez, E.A.; Scagliotti, G.V.; Carbone, D.P.; Aerts, H.; Aisner, D.L.; Bergh, J.; et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J. Thorac. Oncol. 2018, 13, 1818–1831. [CrossRef]
7. Kapadia, N.S.; Valle, L.F.; George, J.A.; Jaggi, R.; D’Amico, T.A.; Dexter, E.U.; Vigneau, F.D.; Kong, F.M. Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 2017, 104, 1881–1888. [CrossRef]
8. Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.R.; Bharat, A.; Bruno, D.S.; Chang, J.Y.; Chirieac, L.R.; D’Amico, T.A.; et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J. Natl. Compr. Cancer Netw. 2021, 19, 254–266. [CrossRef]
9. Lugg, S.T.; Agostini, P.J.; Tikka, T.; Kerr, A.; Adams, K.; Bishay, E.; Kalkat, M.S.; Steyn, R.S.; Rajesh, P.B.; Thickett, D.R.; et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. *Thorax* **2016**, *71*, 171–176. [CrossRef]

10. Prevots, D.R.; Shaw, P.A.; Strickland, D.; Jackson, L.A.; Raebel, M.A.; Bloshky, M.A.; Montes de Oca, R.; Shea, Y.R.; Seitz, A.E.; Holland, S.M.; et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. *Am. J. Respir. Crit. Care Med.* **2010**, *182*, 970–976. [CrossRef]

11. Lee, H.; Myung, W.; Koh, W.J.; Moon, S.M.; Jhun, B.W. Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016. *Emerg. Infect. Dis.* **2019**, *25*, 569–572. [CrossRef]

12. Park, S.C.; Kang, M.J.; Han, C.H.; Lee, S.M.; Kim, C.J.; Lee, J.M.; Kang, Y.A. Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: A nationwide population-based study. *BMJ Pulm. Med.* **2019**, *19*, 140. [CrossRef]

13. Huang, H.L.; Cheng, M.H.; Lu, P.L.; Shu, C.C.; Wang, J.Y.; Wang, J.T.; Chong, I.W.; Lee, L.N. Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan—A Retrospective, Five-Year Multicenter Study. *Sci. Rep.* **2017**, *7*, 16300. [CrossRef] [PubMed]

14. Cowman, S.; van Ingen, J.; Griffith, D.E.; Loeboinger, M.R. Non-tuberculous mycobacterial pulmonary disease. *Eur. Respir. J.* **2019**, *54*, 1900250. [CrossRef]

15. Liao, T.L.; Lin, C.F.; Chen, Y.M.; Liu, H.J.; Chen, D.Y. Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area. *Sci. Rep.* **2016**, *6*, 29443. [CrossRef] [PubMed]

16. Brode, S.K.; Campitelli, M.A.; Kwong, J.C.; Lu, H.; Marchand-Austin, A.; Gershon, A.S.; Jamieson, F.B.; Marras, T.K. The risk of mycobacterial infections associated with inhaled corticosteroid use. *Eur. Respir. J.* **2017**, *50*, 1700037. [CrossRef]

17. Shin, S.H.; Kim, B.G.; Kang, J.; Um, S.W.; Kim, H.; Kim, H.K.; Kim, J.; Shim, Y.M.; Choi, Y.S.; Jeong, B.H. Incidence and Risk Factors of Chronic Pulmonary Aspergillosis Development during Long-Term Follow-Up after Lung Cancer Surgery. *J. Funct.* **2020**, *6*, 271. [CrossRef] [PubMed]

18. Tamura, A.; Suzuki, J.; Fukami, T.; Matsui, H.; Akagawa, S.; Ohta, K.; Hebisawa, A.; Takahashi, F. Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer. *Interact. Cardiovasc. Thorac. Surg.* **2015**, *21*, 650–656. [CrossRef]

19. Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann. Surg. Oncol.* **2010**, *17*, 1471–1474. [CrossRef] [PubMed]

20. Miskovic, A.; Lumb, A.B. Postoperative pulmonary complications. *Br. J. Anaesth.* **2017**, *118*, 317–334. [CrossRef]

21. Griffith, D.E.; Aksamit, T.; Brown-Elliott, B.A.; Catanzaro, A.; Daley, C.; Gordin, F.; Holland, S.M.; Horsburgh, R.; Huitt, G.; Iademarco, M.F.; et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am. J. Respir. Crit. Care Med.* **2007**, *177*, 367–416. [CrossRef] [PubMed]

22. Kwk, N.; Lee, J.H.; Kim, H.J.; Kim, S.A.; Yim, J.J. New-onset nontuberculous mycobacterial pulmonary disease in bronchiectasis: Tracking the clinical and radiographic changes. *BMJ Pulm. Med.* **2020**, *20*, 293. [CrossRef] [PubMed]

23. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am. J. Respir. Crit. Care Med.* **2000**, *161*, 1376–1395.

24. Kim, B.G.; Kim, H.; Kwon, O.J.; Huh, H.J.; Lee, N.Y.; Baek, S.Y.; Sohn, I; Jhun, B.W. Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease. *J. Clin. Med.* **2020**, *9*, 2968. [CrossRef] [PubMed]

25. Koh, W.J.; Jeong, B.H.; Kim, S.Y.; Jeon, K.; Park, K.U.; Jhun, B.W.; Lee, H.; Park, H.Y.; Kim, D.H.; Huh, H.J.; et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. *Clin. Infect. Dis.* **2017**, *64*, 309–316. [CrossRef] [PubMed]

26. Park, Y.; Kim, C.Y.; Park, M.S.; Kim, Y.S.; Chang, J.; Kang, Y.A. Age- and sex-related characteristics of the increasing trend of nontuberculous mycobacterial pulmonary disease in a tertiary hospital in South Korea from 2006 to 2016. *Korean J. Intern. Med.* **2020**, *35*, 1424–1431. [CrossRef]

27. Yamanashi, K.; Marumo, S.; Fukui, M.; Huang, C.L. Nontuberculous Mycobacteria Infection and Prognosis after Surgery of Lung Cancer: A Retrospective Study. *Thorac. Cardiovasc. Surg.* **2017**, *65*, 581–585. [CrossRef]

28. Park, Y.S.; Lee, C.H.; Lee, S.M.; Yang, S.C.; Yoo, C.G.; Kim, Y.W.; Han, S.K.; Shim, Y.S.; Yim, J.J. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. *Int. J. Tuberc. Lung Dis.* **2010**, *14*, 1069–1071.

29. Jhun, B.W.; Moon, S.M.; Jeon, K.; Kwon, O.J.; Yoo, H.; Carriere, K.C.; Huh, H.J.; Lee, N.Y.; Shin, S.J.; Daley, C.L.; et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: A 15-year follow-up study. *Eur. Respir. J.* **2020**, *55*, 1900798. [CrossRef]

30. Ide, S.; Nakamura, S.; Yamamoto, Y.; Kohno, Y.; Fukuda, Y.; Ikeda, H.; Sasaki, E.; Yanagihara, K.; Higashiyama, Y.; Hashiguchi, K.; et al. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. *PLoS ONE* **2015**, *10*, e0128304. [CrossRef]

31. Griffith, D.E.; Girard, W.M.; Wallace, R.J., Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. *Am. Rev. Respir. Dis.* **1993**, *147*, 1271–1278. [CrossRef] [PubMed]

32. Fowler, S.J.; French, J.; Sreenan, N.J.; Foweraker, J.; Condiffe, A.; Haworth, C.S.; Exley, A.R.; Bilton, D. Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. *Eur. Respir. J.* **2006**, *28*, 1204–1210. [CrossRef] [PubMed]

33. Andréják, C.; Nielsen, R.; Thomsen, V.; Duhaut, P.; Sørensen, H.T.; Thomsen, R.W. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. *Thorax* **2013**, *68*, 256–262. [CrossRef]

34. Vento, S.; Cainelli, F.; Temesgen, Z. Lung infections after cancer chemotherapy. *Lancet. Oncol.* **2008**, *9*, 982–992. [CrossRef]
35. Larici, A.R.; del Ciello, A.; Maggi, F.; Santoro, S.I.; Meduri, B.; Valentini, V.; Giordano, A.; Bonomo, L. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics 2011, 31, 771–789. [CrossRef]

36. Koh, W.J.; Chang, B.; Ko, Y.; Jeong, B.H.; Hong, G.; Park, H.Y.; Jeon, K.; Lee, N.Y. Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. Diagn. Microbiol. Infect. Dis. 2013, 75, 225–226. [CrossRef] [PubMed]